6 Anti-Aging Peptides Move Closer to FDA Compounding Approval, Vanta Builds Health Platform

For healthcare providers and health IT innovators, the potential addition of BPC-157, TB-500, and others to the FDA's 503A Bulks List represents a critical shift in the availability of peptide-based regenerative therapies. If finalized, it could enable compounding pharmacies to legally supply these sought-after compounds, integrating with telehealth platforms to offer personalized longevity care directly to consumers.

On July 23–24, 2026, the U.S. FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend the inclusion of six peptide substances—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—on the agency’s 503A Bulks List. This advisory vote marks a pivotal juncture in the regulation of compounded peptides, a sector that has long operated in a gray zone between dietary supplement and unapproved drug. For the burgeoning longevity and wellness market, the recommendation signals a potential federal pathway for legal compounding of these increasingly popular therapies.

“

FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend the inclusion of six peptide substances—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—on the agency’s 503A Bulks List.

The FDA’s 503A Bulks List enumerates bulk drug substances that may be used by licensed compounding pharmacies to prepare patient-specific medications. Inclusion on the list would allow facilities to legally compound these peptides, provided they adhere to applicable quality standards and state pharmacy regulations. The substances recommended—BPC-157 (a peptide fragment with studies suggesting gut and musculoskeletal healing), TB-500 (thymosin beta-4, involved in tissue repair and cell migration), MOTS-c (a mitochondrial-derived peptide linked to metabolic health and exercise capacity), Epitalon (a tetrapeptide associated with telomerase activation and anti-aging), Semax (a nootropic peptide used for cognitive enhancement), and KPV (an anti-inflammatory peptide fragment of alpha-MSH)—have gained substantial traction among biohackers, concierge clinics, and direct-to-consumer telehealth platforms. However, until now, their legal status as compounded substances was uncertain, leaving pharmacies and patients vulnerable to enforcement risk.

The PCAC recommendation is advisory; the FDA retains final authority on whether to officially add these substances to the 503A list. The committee’s deliberation, conducted over a two-day public meeting that reviewed scientific, medical, and stakeholder submissions, nonetheless carries considerable weight. Historically, FDA advisory committee endorsements often foreshadow eventual agency action, though the timeline can stretch months or even years. The agency must balance patient access, safety concerns, and the need to deter commercial-scale compounding that effectively circumvents the new drug approval process.

Vanta Holdings Inc. (CSE:VNTA, OTC PINK:VNTXF, FSE:7BC), a publicly traded consumer health sciences company, issued a press release commending the PCAC vote and detailing its strategic readiness. Vanta claims to have built a comprehensive operating framework for a U.S.-focused peptide platform, encompassing telehealth-enabled commercialization, coordination with FDA-registered compounding pharmacies, peptide manufacturing and fulfillment capabilities, and compliant payment processing. This infrastructure is designed to integrate peptide therapies with Vanta’s existing nutraceutical and premium functional hydration portfolio, positioning the company squarely in the fast-growing longevity and preventive wellness market.